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Title: Association Between Antibiotics in the First Year of Life and Celiac Disease 
 
Abstract:  
Background & Aims: The intestinal microbiota is thought to be involved in pathogenesis of celiac 
disease, along with genetic variants and dietary gluten. The gut microbiota is strongly influenced by 
systemic antibiotics—especially in early life. We explored the association between exposure to a 
systemic antibiotic in the first year of life and risk of diagnosed celiac disease. 
 
Methods: We performed an observational nationwide register-based cohort study. We included all 
children born in Denmark from 1995 through 2012 or Norway from 2004 through 2012. Children 
born in Denmark were followed until May 8, 2015 (age at end of follow-up was 2.3–20.3 years) and 
children born in Norway were followed until December 31, 2013 (age at end of follow-up was 1–10 
years). We collected medical information from more than 1.7 million children, including 3346 with 
a diagnosis of celiac disease. Exposure to systemic antibiotics was defined as a dispensed systemic 
antibiotic in the first year of life. 
 
Results: Exposure to systemic antibiotics in the first year of life was positively associated with 
diagnosed celiac disease in the Danish and in the Norwegian cohort (pooled odds ratio, 1.26; 95% 
CI, 1.16–1.36). We found a dose-dependent relationship between an increasing number of 
dispensed antibiotics and the risk of celiac disease (pooled odds ratio for each additional dispensed 
antibiotic, 1.08; 95% CI, 1.05–1.11). No specific type of antibiotic or age period within the first 
year of life was prominent. Adjustment for hospital admissions with an infectious disease in the 
first year of life did not change the estimates; adjustment for the number of maternally reported 
infections in the child in 2 large sub-cohorts reduced the association slightly (pooled odds ratio, 
1.18; 95% CI, 0.98–1.39). 
 
Conclusion: In a nationwide study of children in Denmark and Norway, we found exposure to 
systemic antibiotics in the first year of life to be associated with a later diagnosis of celiac disease. 
These findings indicate that childhood exposure to systemic antibiotics may be a risk factor for 
celiac disease. 
 
KEY WORDS: microbiome; epidemiology; population; autoimmunity 
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Celiac disease is a chronic immune-mediated enteropathy driven by the ingestion of dietary gluten 
in genetically predisposed individuals.1 The presence of one of the human leukocyte antigens 
(HLA) DQ2 or DQ8 and exposure to dietary gluten are necessary but insufficient causes of celiac 
disease. Only a few individuals carrying HLA DQ2 or DQ8 develop celiac disease, suggesting that 
additional factors are involved in disease development. Non-HLA genetic variants associated with 
celiac disease are thought to account for a proportion of the disease risk.2 Environmental factors, in 
addition to gluten, are not well-established and equivocal. 
The role of the gut microbiota has attracted increasing interest as a contributing factor in the 
pathogenesis of autoimmune diseases,3 including celiac disease.4 Studies have reported differences 
in gut microbiota when comparing patients with active celiac disease to healthy controls.5, 6 
The gut microbiota evolves dramatically in the first years of life7 and stabilizes at two to three years 
of age.8 The gut microbiota in early life influences the maturation of the immune system9 and plays 
a role in the degradation of gluten in the gastrointestinal tract and may thereby affect the 
immunogenicity of gluten peptides.10 Antibiotic exposure has a strong and sustained impact on the 
developing and unstable intestinal ecosystem.11, 12  
The objective of the present study was to study whether use of systemic antibiotics in the first year 
of life was associated with diagnosed celiac disease in two large independent nationwide cohorts 
with different prevalence of diagnosed celiac disease. 
 
MATERIALS AND METHODS 
This study was an observational register-based study of two independent nationwide cohorts, one 
from Denmark and one from Norway, using data from administrative and health administrative 
registers. All registrations were linked at the individual-level. Based on data availability, all 
children who were born in Denmark from January 1, 1995, to December 31, 2012, and all children 
who were born in Norway from January 1, 2004, to December 31, 2012 and registered in the 
medical birth registers were included in the study. In addition, we included data from two large 
birth cohorts for a subgroup of the included children to examine the effects of adjusting for the 
number of maternally reported infections in the child and duration of breastfeeding as potential 
confounders. 
 
Outcome: Diagnosed celiac disease  
The outcome was diagnosed celiac disease (International Classification of Diseases 10th Revision 
(ICD-10) K90.0). 
The Danish National Patient Register includes all the inpatients and outpatients seen in Danish 
hospitals.13 To identify children with celiac disease, we included all the registrations of celiac 
disease and confirmed the diagnoses with duodenal biopsies registered in the Danish Pathology 
Data Bank and celiac disease-specific antibodies from medical records.14 We considered the 
diagnosis to be confirmed if a duodenal biopsy compatible with celiac disease i.e. Marsh 2–315 
(81% of the confirmed cases) or if a measurement of IgA tissue transglutaminase 2 antibodies at 10 
or more times the upper limit of normal or a positive IgA endomysial antibody measurement (70% 
of the confirmed cases) was registered. The end of the follow-up in Denmark was May 8, 2015.14 
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The Norwegian National Patient Register includes diagnoses from Norwegian hospitals and 
outpatient clinics.16 We considered all the children with two or more registrations of celiac disease 
as having diagnosed celiac disease. The use of two or more registrations has been previously 
validated for participants in the Norwegian Mother and Child Cohort Study (MoBa).17 The data did 
not include the exact dates of registration but were available as cumulative data for each year since 
2008. Children diagnosed in the period 2004–2008 were registered at the recommended annual 
hospital follow-up from 2008 onwards, but the exact year of diagnosis was unavailable. The end of 
follow-up in Norway was December 31, 2013. 
 
Exposure: Dispensed systemic antibiotics 
The main exposure was a systemic antibiotic dispensed from a pharmacy in the first year of life. 
In Denmark and Norway, antibiotics are available by prescription only. All antibiotics dispensed 
outside of hospitals (90% of antibiotics used in Denmark, and 93% of antibiotics used in Norway) 
are registered at the individual level in national prescription registers and drugs are classified 
according to the Anatomical Therapeutic Chemical (ATC) Coding System.18, 19 We included all 
systemic antibiotics (ATC J01) dispensed in the first two years of life. The use of antibiotics from 
one to two years of age was included in sub-analyses. 
In the Norwegian Prescription Register, approximately 30% of the prescriptions from the first year 
of life lacked ID numbers (range, 17–56% per year) (Table S.1) which excluded the individual-level 
linkage. Prescriptions with missing ID numbers were not included in the study, and thus the 
exposure to antibiotics was an underestimate and some children exposed to antibiotics may have 
been misclassified as unexposed. However, there are no reasons to assume that this is dependent on 
celiac disease diagnosis. 
Antibiotic treatment for infections requiring hospitalization is often completed outside of the 
hospital and in these cases dispensed antibiotics are usually registered. An exception occurs in the 
cases of neonatal infections, which are typically treated by intravenous antibiotics in the hospital 
only. In the Danish cohort, we constructed a proxy variable for antibiotic exposure in the neonatal 
period as admissions in the neonatal period (0–28 days of age) of at least three days duration with 
an infectious diagnosis, for included diagnoses, please refer to Table S.2. The proxy variable for 
neonatal exposure in the Danish cohort was only used in the sub-analysis of the age at first 
exposure. In the Norwegian cohort, we included information on systemic antibiotics administered at 
the neonatal ward (yes or no) from the Norwegian Medical Birth Register. 
Exposure to antibiotics was categorized as any (≥1) dispensed antibiotic and the number of 
dispensed antibiotics with no dispensed antibiotic in this age period or prior to this age period as a 
reference. We categorized the types of antibiotics based on the most commonly prescribed groups 
of antibiotics. See Table S.3 for details. 
 
Other variables 
We included information from the Danish Civil Registration System, the Danish National Patient 
Register, the Danish Medical Birth Register, the Danish Population’s Education Register, the 
Norwegian Medical Birth Register, and Statistics Norway on the following potential confounders: 
gestational age, birthweight, season of birth, maternal parity, maternal age, maternal educational 
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level, maternal smoking during pregnancy, maternal pre-pregnancy body mass index (BMI), 
maternal country of birth, and maternal diabetes diagnosed prior to the birth of the child. We 
included information from the Danish National Patient Register on the child’s hospital admissions 
for infections in the first year of life, chromosomal and autoimmune diseases known to be 
associated with celiac disease and diagnosed prior to the first registration of celiac disease, and 
maternal autoimmune disease diagnosed prior to the birth of the child. From the Danish National 
Prescription Register, we included dispensed antifungals for topical use (ATC D01A) as a negative 
control. From the Norwegian National Prescription Register, we included dispensed insulin (ATC 
A10A) and considered children with two or more registrations to have type 1 diabetes. See the 
supplementary material (Section 1.1 Registers and variables and Table S.2) for additional 
information. 
 
The Danish National Birth Cohort (DNBC) and the Norwegian Mother and Child Cohort 
Study (MoBa) 
To examine the effect of adjusting for the number of maternally reported infections in the child and 
the duration of breastfeeding as potential confounders, we included data from two large national 
birth cohorts with overlapping study periods: the Danish National Birth Cohort (DNBC)20 and the 
Norwegian Mother and Child Cohort Study (MoBa).21 
The DNBC includes approximately 30% (94,000 children) of all children born in Denmark from 
1998 to 2003. The mothers answered questionnaires about infectious diseases in the child and infant 
feeding via computer-assisted telephone interviews (questionnaires) when the child was 6 and 18 
months old. The mothers were asked if the child had had a specific symptom or disease during the 
periods of 0–6 months of age (common cold, diarrhea, acute otitis media, bronchitis or pneumonia) 
and 6–18 months (common cold, diarrhea, acute otitis media, bronchitis, pseudocroup, tonsillitis, 
fever, pneumonia or scarlatina) respectively. Fungal infections (oral thrush and other fungal 
infections) were included as a separate variable. The mothers were asked how often the disease 
lasted more than three days (common cold, diarrhea, tonsillitis and fever) or how many times they 
had had the disease (acute otitis media, bronchitis, pneumonia, pseudocroup and scarlatina). The 
mothers were also asked about infant feeding including the duration of breastfeeding. The 
questionnaires are available in Table S.4 and at www.dnbc.dk. 
The MoBa recruited participants from all over Norway from 1999 to 2008 and the women 
consented to participation in 41% of the pregnancies corresponding to approximately 114,000 
participating children. We included only children born in our study period (2004–2008). The 
mothers filled in questionnaires about infectious diseases in the child and infant feeding when the 
child was 6 and 18 months old. The mothers were asked if the child had had specific health 
problems (common cold, diarrhea, throat infection, ear infection, bronchitis/pneumonia, diarrhea, 
urinary tract infection or pseudocroup) and the number of times they occurred in the age periods 0–
6 months of age (6-month questionnaire), 6–12 months of age, and 12-18 months of age (18-month 
questionnaire). Mårild et al. have previously reported that the number of infectious episodes is 
associated with celiac disease in the MoBa.22 Information on fungal infections was not available in 
the MoBa. The mothers were also asked about breastfeeding during the first week of life and each 
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month until 6 months of age and in 3-month intervals from 6 to 18 months of age. The 
questionnaires are available in Table S.4 and at www.fhi.no/en/studies/moba. 
The number of infectious episodes was estimated as the sum of positive indications of infections 
from the questionnaires at 6 and 18 months of age. In the DNBC, common cold, diarrhea, tonsillitis 
and fever of less than three days was not included because the mothers were asked only about 
symptoms lasting more than three days. If the answers for one or more type of infection were 
missing, the values were set to no infectious episodes of this type and this may also have led to 
underestimation of the total number of infectious episodes. 
The duration of breastfeeding was categorized as 0–3 months, 3–6 months, 6–9 months, 9–12 
months, and 12 months or longer. We did not distinguish between exclusive breastfeeding or partial 
breastfeeding. 
 
Statistics 
The data were analyzed using a logistic regression model with robust cluster variance estimation to 
take into account siblings with the same mother. All the analyses were adjusted for year of birth to 
take into account differences in follow-up times and the increasing prevalence of celiac disease and 
the propensity to prescribe antibiotics in the study period. Furthermore, all the analyses were 
adjusted for sex as a confounding variable because girls are more likely to develop celiac disease1 
and boys are more often treated with antibiotics in early life.19 In the Danish cohort, we excluded 
children diagnosed before or in the exposed age period to minimize the risk of reverse causality. 
This was not possible in the Norwegian cohort because the exact age at diagnosis was not known. 
The Danish cohort and the Norwegian cohort were analyzed separately. The estimates were pooled 
using a fixed-effect meta-analysis. The degree of statistical heterogeneity was assessed by the I2 
test.23 
The main exposure was dispensed systemic antibiotics in the first year of life. As a sensitivity 
analysis, we examined dispensed antibiotics in the first 3, 6, 9, 12, 18 and 24 months of life both as 
the age period for the first antibiotic exposure, the cumulative exposure since birth, and any 
exposure in a given age period regardless of previous exposures. 
We examined the effects of adjusting for the following additional potential confounders: hospital 
contact with an infectious disease in the first year of life, gestational age, weight for gestational age, 
season of birth, maternal parity, maternal educational level, maternal age, maternal smoking during 
pregnancy, maternal country of birth, maternal autoimmune disease diagnosed prior to the birth of 
the child, and maternal pre-pregnancy BMI. 
Information in the DNBC and the MoBa was available for the first 18 months of life. For the 
children participating in the DNBC or the MoBa, we analyzed the association between antibiotic 
exposure in the first 18 months of life and diagnosed celiac disease and the effect of adjusting for 
the number of maternally reported infections in the child, the number of fungal infections in the 
child (DNBC) and duration of breastfeeding.  
We stratified the analyses for the age at celiac disease diagnosis (first registration): 1–4 years of 
age, 5–8 years of age and 9–19 years of age. In the Danish cohort, we stratified the analyses for the 
presence of associated comorbidity in the child (yes/no). As a post hoc analysis, we stratified the 
analyses for the mode of delivery (both cohorts), autoimmune disease in the mother or the child 
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(Danish cohort) and a diagnosis of type 1 diabetes in the mother or the child (both cohorts). We 
tested for evidence for effect modification by testing for statistical interaction between the potential 
effect modifier and antibiotic exposure in the first year of life using the log likelihood ratio test. 
To examine the effect of the model choice, we analyzed the Danish data using a Cox proportional 
hazards regression model with follow-up time from one year of age to the first event of diagnosis, 
emigration, death, or January 1, 2015. We adjusted for year of birth and sex. 
To examine potential bias due to missing ID numbers in the Norwegian National Prescription 
Register, we stratified the analyses according to the proportion of missing ID numbers: 2004–2007 
(42% missing), 2008–2009 (26% missing), and 2010–2013 (20% missing). See the supplementary 
material (Table S.1). 
To test the effect of the criteria for diagnosed celiac disease, we conducted the main analysis using 
one or more registrations of celiac disease in the national patient registers, two or more registrations 
of celiac disease in the national patient registers (the definition used in the Norwegian cohort) and 
diagnoses confirmed by a registration of a duodenal biopsy or serology compatible with a celiac 
disease diagnosis (the definition used in the Danish cohort, only available in the Danish cohort). See 
the supplementary material (Section 3. Definition of outcome). 
A 95% confidence interval (95% CI) for the odds ratio (OR) that excluded 1.00 was considered 
statistically significant. All the analyses were conducted using Stata version 15 statistical software 
(StataCorp LP, College Station, TX, USA). 
 
Ethics 
The Danish study was approved by the Danish Data Protection Agency. Patient consent from the 
participants and notification of the regional committees on health research ethics was not required 
as this was a register-based study not including human biological material. The DNBC was 
approved by the Committee on Biomedical Research Ethics (KF 01-471/94) and the Danish Data 
Protection Agency. 
The Norwegian study was approved by the Norwegian Data Inspectorate and the Regional 
Committee for Medical and Health Research Ethics (2013/2114-12). The study was exempted from 
individual consent as it was a register-based study with a low risk of personal identification. The 
data collection in the MoBa has a license from the Norwegian Data Inspectorate and approval from 
the Regional Committee for Medical Research Ethics. 
Informed consent was obtained from all participants in the DNBC and the MoBa. 
 
RESULTS 
For the analyses in the Danish cohort, we included 1,168,656 children after exclusions for 
inconsistent data in personal identification numbers (n=39). The median age at end of follow-up 
was 11.6 years (range: 2.3–20.3 years). Celiac disease was registered for 1,427 children (0.12%). 
Systemic antibiotics in the first year of life were dispensed to 451,196 children without celiac 
disease (38.7%) and to 622 children with celiac disease (43.6%). 
For the analyses in the Norwegian cohort, we included 537,457 children after exclusions for 
inconsistent data in personal identification numbers (n=3,579). The median age at end of follow-up 
was 5.4 years (range: 1–10 years). Celiac disease was registered for 1,919 children (0.36%). 
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Systemic antibiotics in the first year of life were dispensed to 98,538 children without celiac disease 
(18.4%) and to 390 children with celiac disease (20.3%). In Norway, the proportion of children with 
a dispensed systemic antibiotic was approximately 30% higher than reported here because 
prescriptions lacking ID numbers were not included in this study. 
Table 1 and Table S.5 show the distribution of the potential confounders according to antibiotic 
exposure in the first year of life. Antibiotic exposure in the first year of life was less common in 
girls, children born in autumn, firstborn children, children of mothers with a higher educational 
level and children who were breastfed for a longer period of time. 
 
Antibiotic exposure and celiac disease  
Exposure to systemic antibiotics in the first year of life was positively associated with diagnosed 
celiac disease in both the Danish and the Norwegian cohort (pooled adjusted OR: 1.26; 95% CI: 
1.16–1.36) with a dose-dependent relationship between an increasing number of dispensed 
antibiotics and the risk of celiac disease (pooled adjusted OR for each additional dispensed 
antibiotic: 1.08; 95% CI: 1.05–1.11). Adjustment for hospital contacts with an infectious disease in 
the first year of life (only available in the Danish cohort) (Table 2) and other potential confounders 
(Table S.6) did not change the estimates substantially. 
Analysis of the Danish data using a Cox proportional hazards regression model did not change the 
association (data not shown). 
Table 2 shows the association between antibiotic exposure in the first 6, 12, 18, and 24 months of 
life and celiac disease. Antibiotic exposure was associated with celiac disease in all age groups 
except exposure from 0–6 months of age in the Norwegian cohort. 
The association between age at first exposure and celiac disease is shown in figure 1A and the 
association between age at any exposure and celiac disease is shown in figure 1B. The association 
between exposure to different types of antibiotics in the first year of life and the risk of celiac 
disease is shown in figure 1C-D. The associations did not appreciably differ by type of antibiotic or 
age at exposure. 
 
Stratification for age at diagnosis, associated comorbidity and mode of delivery 
We found a positive association for all the groups of the age at diagnosis (Table 3). 
Stratification for the presence of an associated comorbidity diagnosed prior to celiac disease 
showed no association between antibiotic exposure and risk of celiac disease in the group of 
children with an associated comorbidity. Post hoc analyses showed no association between 
antibiotics and celiac disease in the group with a diagnosed associated autoimmune disease in the 
mother or the child (Danish cohort) or the groups with diagnosed type 1 diabetes in the mother or 
the child (Table 3). 
Table 3 shows comparable estimates across strata for mode of delivery with no evidence of effect 
modification. 
 
Maternally reported infections in the child and duration of breast-feeding (DNBC/MoBa) 
We included 55,082 children (100 with celiac disease) from the DNBC and 53,257 children (464 
with celiac disease) from the MoBa with completed questionnaires about breastfeeding and 
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infectious diseases 6 and 18 months postpartum. Adjustment for breastfeeding did not change the 
association. Adjustment for the number of maternally reported infections in the child weakened the 
association slightly. In DNBC, adjustment for the number of maternally reported fungal infections 
in the child did not change the association. (Table 4).  
 
Negative control 
Antifungal drugs for topical use were dispensed to 118,534 children (10.1%) in the Danish cohort. 
The children registered with dispensed systemic antibiotics were more likely to be registered with 
dispensed antifungal for topical use (p<0.0001). A dispensed topical antifungal was not associated 
with celiac disease (adjusted OR: 1.08; 95% CI: 0.91–1.28). 
 
DISCUSSION 
In this observational study of two large independent nationwide cohorts of more than 1.7 million 
children (3,346 diagnosed with celiac disease), a dispensed systemic antibiotic in the first year of 
life was consistently positively associated with diagnosed celiac disease. We found a dose-
dependent relationship with an increasing number of dispensed antibiotics. No specific type of 
antibiotic in the first year of life or age at exposure were prominent, suggesting no specific 
vulnerable age at exposure and a similar effect for all the antibiotic types, although the low use of 
some antibiotics limited the study of these types.  
Previous studies have reported conflicting findings on the association between early antibiotic 
exposure and risk of celiac disease.24-29 Our main findings agree with those of Canova el al.25 who 
found an incidence rate ratio of 1.31 (95% CI: 1.10–1.56) for celiac disease confirmed by pathology 
reports (510 cases). A Swedish study24 used parentally reported antibiotics during the first six 
months of life and diagnosed celiac disease until two years of age in a post hoc analysis without any 
adjustments and with low power (373 cases). They found no statistically significant association, 
although the point estimate was comparable to our findings and those of Canova et al. (OR: 1.2; 
95% CI: 0.87–1.6). In a recent study from the TEDDY cohort, a multinational cohort of children at 
high genetic risk of type 1 diabetes and celiac disease, Kemppainen et al.26 found no association 
between parentally reported antibiotic exposure and persistently positive celiac disease -specific 
antibodies at four years of age (783 cases of celiac disease autoimmunity). In contrast to population-
based cohort studies that do not include cases of undiagnosed children, screening for celiac disease 
autoimmunity as the outcome captured all the children with celiac disease and some who never will 
develop celiac disease. Our findings may be affected if factors related to being diagnosed as 
opposed to remaining undiagnosed are related to the use of antibiotic. 
Previous studies have reported differences in risk factors for children with both type 1 diabetes and 
celiac disease.30 When we stratified our analyses for a diagnosis of type 1 diabetes in the mother or 
the child (post hoc analysis), we found no association between antibiotic exposure and diagnosed 
celiac disease in the group with type 1 diabetes diagnosed in the mother or the child in accordance 
with the findings in the TEDDY cohort. However, we found no evidence for effect modification. 
Mårild et al.27 reported from a Swedish register-based study that antibiotic exposure up to three 
years prior to the diagnosis was associated with celiac disease at all ages. This suggests that 
antibiotic exposure not only in early life but exposure at any age may be associated with celiac 
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disease. However, caution needs to be taken as these associations are more prone to bias by reverse 
causation. In our study, the association was at least as strong for exposure from 0-24 months as for 
0-12 months. In a sub-analysis, Mårild at al. found that exposure in the first six months of life was 
associated with celiac disease in accordance with our findings but the study did not have sufficient 
power for such a sub-analysis (OR: 2.26; 95% CI: 0.55–9.25). 
Adjustment for potential confounders did not change the conclusion of our study. The knowledge 
about risk factors for celiac disease in addition to gluten intake and HLA DQ2/DQ8 is limited. 
Therefore, it is difficult to select relevant confounders for adjustment. We examined potential 
confounders also included in other studies and were reassured that adjustments only altered our 
estimates slightly and did not change our conclusions. We found no evidence for effect 
modification by mode of delivery. Maternal use of antibiotics during pregnancy,31 age at gluten 
introduction and use of proton pump inhibitors may also be effect modifiers but are not included in 
this study.  
Infections in early life have been proposed to contribute to celiac disease development and are thus 
important potential confounders. Studies have reported an association with specific infectious 
agents,32, 33 types of infection,22, 25 as well as the overall number of hospital admissions for 
infectious diseases,25 medically attended infectious diseases,34 and parentally reported infectious 
diseases.22, 35 The association has been reported for both viral32, 33 and bacterial infections.22, 25, 34 
Infectious diseases may be present without antibiotic treatment, but antibiotic treatment is rarely 
used in absence of an infectious disease. Infections with severe symptoms are more likely to be 
treated with antibiotics but assuming that infections treated with antibiotics are bacterial and 
infections not treated with antibiotics are viral is not tenable. Disentangling the effect of infections 
and antibiotics is therefore difficult in an observational study lacking details on the infections and 
indication for antibiotic use. Adjustment for hospital admission with an infectious disease did not 
change our conclusions; these infections are likely to represent the most severe infectious episodes. 
We were able to adjust for the number of maternally reported infections in the child for the 
subgroup of children participating in the DNBC/MoBa. This adjustment weakened the association 
slightly, indicating that infections may be a confounder, but the association for antibiotic exposure 
remained. Maternally reported infectious episodes at 6 and 18 months may be an imprecise measure 
for the actual incidence. The imprecision is probably unrelated to diagnosed celiac disease, but may 
result in residual confounding in our analysis. 
In the Norwegian cohort, some children were misclassified as unexposed to antibiotics when they 
were in fact exposed because a considerable number of prescriptions to young children lacked the 
personal identification number. We have no reason to suspect that this misclassification depends on 
the risk of diagnosed celiac disease or other variables included in the study and expect the 
misclassification to bias the estimates toward no association (Table S.7 and S.8). In the Norwegian 
cohort, we found no association between antibiotics and celiac disease in the first 6 months of life. 
The most likely explanation for the lack of association in this age group that this is the age group 
with most prescriptions lacking ID number and thus children misclassified as unexposed to 
antibiotics. 
We have previously demonstrated that the registration of celiac disease diagnoses in the national 
patient registers is prone to misclassification14 and therefore we used validated diagnoses to ensure 
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a high validity of the included cases. In the Danish cohort, the prevalence of diagnosed celiac 
disease was higher than reported for registrations of celiac disease in the Danish National Patient 
Register until 2010 (0.084%)36 even though we used a more strict case definition with validation of 
the diagnosis. This reflects an increased prevalence of diagnosed celiac disease in the Danish 
pediatric population. In the Norwegian cohort, the prevalence of diagnosed celiac disease was 
slightly lower than previously reported for registrations of celiac disease in the Norwegian National 
Patient Register (0.38%).37 The difference resulted from a more strict definition of celiac disease: 
two or more registrations in the Norwegian National Patient Register in the present study compared 
to one or more registrations of celiac disease in the previous study; and a shorter average follow-up 
time. 
It is well-known that celiac disease is underdiagnosed. Factors associated with a diagnosis of celiac 
disease as opposed to remaining undiagnosed are unclear but are likely to include both symptoms of 
disease, belonging to a risk group, and parental health-seeking behavior. The propensity to use 
antibiotics may also be associated with a certain parental health-seeking behavior. Health-seeking 
behavior may thus be a confounder for the association between antibiotics and diagnosed celiac 
disease if the two types of health-seeking behavior are related. We expected that the health-seeking 
behavior leading to increased propensity for an antibiotic prescription was comparable to the health-
seeking behavior increasing the propensity for prescriptions for other medications such as 
antifungals for topical use. We found an association between antifungals for topical use and 
antibiotics, but no association with the risk of celiac disease. Therefore, we do not find it likely that 
this health-seeking behavior is an important confounder for this study. Furthermore, we found 
comparable estimates in both cohorts although the proportion of diagnosed children compared to 
undiagnosed children, most likely, is higher in the Norwegian cohort reflected in the higher 
prevalence of diagnosed celiac disease. The true prevalence of celiac disease in the pediatric 
population of Denmark and Norway is unknown. 
The diagnosis of celiac disease may be a long process with significant diagnostic delay. We cannot 
exclude that our findings are attributable to reverse causality, meaning that the symptoms of celiac 
disease mimic an infection, exaggerate symptoms of infections, or increase the risk of infectious 
diseases thereby increasing the propensity for prescriptions for antibiotics. However, we found that 
the association between antibiotics in the first year of life and celiac disease was comparable across 
the strata of age at diagnosis, making it less likely that our findings are attributable to reverse 
causality. Furthermore, studies have reported a very low prevalence of celiac disease-specific 
antibodies before one year of age.38 
This study, the largest of its kind on this subject with a long follow-up period including two 
independent study populations and adjusting for several potential confounders including infections, 
suggests that antibiotic exposure in early life may be a risk factor for celiac disease. Exposure to 
antibiotics can by no means be regarded as the main contributing factor for development of celiac 
disease, but this study suggests that antibiotics is an important candidate maybe in combination with 
other factors. Future studies should attempt to separate the effect of infections and antibiotics by 
using more detailed information on indication for use of antibiotics and type of infections preferably 
by using biomarkers; and to elaborate on types and ages of exposure and interaction between risk 
factors and if the effect of antibiotic differs between risk groups. 
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Figure 1. 
Odds ratio for celiac disease with 95% confidence interval adjusted for year of birth and sex when 
comparing A) age at first exposure to a systemic antibiotic with no exposure prior to this age period 
B) age at exposure to a systemic antibiotic with no exposure in this age period C) type of antibiotic 
at first exposure to no antibiotic exposure in the first year of life D) exposure to different types of 
antibiotic with no exposure to this type of antibiotic in the first year of life. 
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Table 1. Distribution of selected characteristics and potential confounders by dispensed 
systemic antibiotic in the first year of life. 
Characteristic 
Denmark Norway 
No dispensed 
antibiotics in the 
first year of life 
n=716,838 
≥1 dispensed 
antibiotics  in the 
first year of life 
n=451,818 
No dispensed 
antibiotics  in the 
first year of life 
n=438,529 
≥1 dispensed 
antibiotics in the 
first year of life 
n=98,928 
 
Number (%a) Number (%a) Number (%a) Number (%a) 
Celiac disease      
   Yes 805 (0.11) 622 (0.14) 1,529 (0.35) 390 (0.39) 
   No 716,033 (99.9) 451,196 (99.9) 437,000 (99.7) 98,538 (99.6) 
Sex     
   Male 347,391 (48) 252,278 (56) 219,677 (50) 56,199 (57) 
   Female 369,447 (52) 199,540 (44) 218,852 (50) 42,729 (43) 
Season of birth     
   Winter (December-February) 170,195 (24) 104,680 (23) 102,075 (23) 23,551 (24) 
   Spring (March-May) 165,286 (23) 129,008 (29) 110,441 (25) 27,891 (28) 
   Summer (June-August) 189,336 (26) 120,502 (27) 118,382 (27) 25,231 (26) 
   Autumn (September-
November) 192,021 (27) 97,628 (22) 107,631 (25) 22,255 (22) 
Parity      
   First child 338,728 (47) 174,306 (39) 190,588 (43) 35,876 (36) 
   Second or more child 371,701 (52) 273,897 (61) 247,941 (57) 63,052 (64) 
  Missing 6,409 (0.9) 3,615 (0.8) 0 0 
Maternal educational levelb 
  
  
   Compulsory education 134,713 (19) 98,812 (22) 70,334 (16) 17,544 (18) 
   Medium length 324,113 (45) 214,981 (48) 124,131 (28) 29,823 (30) 
   Higher education 232,095 (32) 126,330 (28) 226,263 (52) 47,747 (48) 
   Missing 25,917 (3.6) 11,695 (2.6) 17,801 (4.1) 3,814 (3.9) 
Maternal age     
   <25 years old 96,338 (13) 66,174 (15) 72,274 (16) 16,462 (17) 
   25-35 years old 494,567 (69) 316,435 (70) 282,095 (64) 64,787 (65) 
   ≥35 years 125,923 (18) 69,200 (15) 84,160 (19) 17,679 (18) 
   Missing 10 (-) 9 (-) 0 0 
Associated co-morbidityc     
   Yes 4,171 (0.58) 2,980 (0.66) N/A N/A 
   No 712,667 (99.4) 448,838 (99.3) N/A N/A 
Type 1 diabetes in the child     
   Yes 1,726 (0.24) 1,115 (0.25) 690 (0.16) 151 (0.15) 
   No 715,112 (99.8) 450,703 (99.8) 437,839 (99.8) 98,777 (99.8) 
Type 1 diabetes in the mother     
   Yes 3,469 (0.48) 2,567 (0.57) 1,966 (0.45) 609 (0.62) 
   No 713,369 (99.5) 449,351 (99.5) 436,563 (99.6) 98,319 (99.4) 
Hospitalization with infection     
   Yes 73,396 (10) 100,192 (22) N/A N/A 
   No 643,442 (90) 351,626 (78) N/A N/A 
Children participating in 
DNBC/MoBa 
No dispensed 
antibiotics  in the 
first 18 months of 
life 
(n=21,151) 
≥1 dispensed 
antibiotics in the 
first 18 months of 
life 
(n=33,931) 
No dispensed 
antibiotics in the 
first 18 months of 
life 
(n=32,185) 
≥1 dispensed 
antibiotics in the 
first 18 months of 
life 
(n=21,072) 
 
Number (%a) Number (%a) Number (%a) Number (%a) 
Maternally reported 
infections in the child     
   0-3 episodes 5,782 (27) 2,932 (9) 6,113 (19) 1,844 (9) 
   4-6 episodes 7,864 (37) 8,771 (26) 10,653 (33) 4,830 (23) 
   7-9 episodes 3,686 (17) 7,239 (21) 8,215 (26) 5,673 (27) 
   ≥10 episodes 3,819 (18) 14,989 (44) 7,204 (22) 8,725 (41) 
Duration of breastfeeding     
   0-3 months 2,449 (12) 5,385 (16) 2,581 (8) 2,165 (10) 
   3-6 months 3,150 (15) 6,191 (18) 2,596 (8) 1,934 (9) 
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   6-9 months 6,137 (29) 9,607 (28) 5,603 (17) 3,917 (19) 
   9-12 months 4,472 (21) 6,485 (19) 8,372 (26) 5,282 (25) 
   ≥12 months 4,943 (23) 6,263 (18) 13,033 (40) 7,774 (37) 
Maternally reported fungal 
infections in the child     
   0 episodes 13,978 (66) 21,216 (63) N/A N/A 
   1-2 episodes 6,282 (30) 10,806 (32) N/A N/A 
   ≥ 3 episodes  891 (4) 1,909 (6) N/A N/A 
Additional characteristics and potential confounders are shown in Table S.5. 
a The denominator is the total number of children without or with a registration of a dispensed 
antibiotic in each country. The percentages may not add up to 100 because of rounding. 
b
 The classification of maternal educational levels in Denmark and Norway is not 
straightforwardly comparable due to differences in the classification of educational levels: 
Denmark: Compulsory education: 10 years. Medium length: Additional four years of vocational 
education or 3 years of general education leading to a university admission certification possibly 
followed by 1-2 years of further education. Higher education: Education beyond medium length. 
Norway: Compulsory education: 10 years. Medium length: Additional 4 years of vocational 
education or 3 years of general education leading to a university admission certification. Higher 
education: Education beyond medium length. 
c
 Prior to the first registration of celiac disease, the child was registered in the Danish National 
Patient Register with a diagnosis of type 1 diabetes (ICD-10 E10 E14), autoimmune thyroid 
disease (ICD-10 E03.9 E05 E06.3), autoimmune hepatitis (ICD-10 K73.2 K75.4) or juvenile 
rheumatoid arthritis (ICD-10 M08.0). 
 
Abbreviations: 
DNBC: The Danish National Birth Cohort. MoBa: The Norwegian Mother and Child Cohort 
Study. N/A: Not available. 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Table 2. Association between dispensed systemic antibiotics and diagnosed celiac disease. 
 Denmark Norway Pooled 
 
n=1,168,656 
(1,427 casesa) 
n=537,457 
(1,919 cases) 
n=1,706,113 
(3,346 cases) 
 
OR (95% CI)b OR (95% CI)b OR (95% CI)b 
Antibiotic exposure in the first year of life (0–12 months)    
Any antibiotics (yes/no) 1.32 (1.18–1.47) 1.21 (1.08–1.36) 1.26 (1.16–1.36)g 
Number of dispensed antibiotics 1.08 (1.05–1.12) 1.09 (1.04–1.15) 1.08 (1.05–1.11)g 
+adjustment for hospital contact with infectionc    
Any antibiotics (yes/no) 1.32 (1.18–1.47) N/A N/A 
Number of dispensed antibiotics 1.08 (1.05–1.12) N/A N/A 
Cumulative exposure since birthd    
0–6 months    
Any antibiotics (yes/no) 1.26 (1.06–1.49) 0.99 (0.81–1.19) 1.11 (0.97–1.25)h 
Number of dispensed antibiotics 1.17 (1.08–1.27) 1.00 (0.86–1.16) 1.12 (1.04–1.20)i 
0–18 months    
Any antibiotics (yes/no) 1.34 (1.20–1.50) 1.27 (1.16–1.39) 1.30 (1.20–1.39)g 
Number of dispensed antibiotics 1.08 (1.06–1.10) 1.08 (1.06–1.11) 1.08 (1.06–1.10)g 
0–24 months    
Any antibiotics (yes/no) 1.35 (1.19–1.53) 1.30 (1.19–1.42) 1.32 (1.22–1.41)g 
Number of dispensed antibiotics 1.06 (1.04–1.07) 1.07 (1.05–1.08) 1.06 (1.05–1.08)g 
Age at first exposuree 
   
6–12 months 1.30 (1.16–1.46) 1.31 (1.15–1.49) 1.30 (1.19–1.42)g 
12–18 months 1.18 (1.02–1.37) 1.26 (1.12–1.43) 1.22 (1.11–1.34)g 
18–24 months 1.18 (0.96–1.46) 1.25 (1.08–1.45) 1.23 (1.08–1.37)g 
Exposure in specified age periodsf    
Any antibiotics 6–12 months 1.28 (1.15–1.42) 1.32 (1.16–1.49) 1.30 (1.19–1.40)g 
Any antibiotics 12–18 months 1.23 (1.10–1.37) 1.34 (1.21–1.49) 1.28 (1.19–1.38)g 
Any antibiotics 18–24 months 1.20 (1.07–1.34) 1.29 (1.16–1.43) 1.25 (1.15–1.34)g 
a Analyses in the Danish cohort excluded children diagnosed prior to or during the time periods 
0–6 months, 6–12 months, 12–18 months, 18–24 months; a maximum of 61 children were 
excluded. 
b
 Odds ratio (OR) with 95% confidence interval (CI) for celiac disease when comparing children 
with dispensed systemic antibiotics with children with no dispensed antibiotics as a reference; 
adjusted for year of birth and sex. 
Additional adjustment for gestational age, weight for gestational age, season of birth, maternal 
parity, maternal educational level, maternal age, maternal smoking during pregnancy, maternal 
country of birth, maternal autoimmune diseases, and maternal pre-pregnancy BMI did not 
change the conclusions. Details are described in the supplementary material. 
c Further adjusted for a hospital contact with an infectious disease in the first year of life (see 
included ICD-10 codes in the supplementary material, Table S.2). 
d The reference in each analysis was no dispensed antibiotics in this age period. 
e The reference in each analysis is no dispensed antibiotics prior to this age period. If a child was 
previously exposed, they were excluded from the analysis. 
f The reference in each analysis was no dispensed antibiotics in this specific age period. 
g
 The I2 test for heterogeneity: 0.0%. 
h
 The I2 test for heterogeneity: 60%.  
i
 The I2 test for heterogeneity: 76%.  
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Table 3. Stratification for the presence of an associated comorbidity and age at diagnosis. 
 Denmark Norway 
 
Number included 
in analysis (cases) OR (95% CI)
a
 
LRT for 
statistical 
interactionb 
Number 
included in 
analysis 
(cases) 
OR (95% CI)a 
LRT for 
statistical 
interactionb 
Diagnosed associated comorbidity in 
the childc       
   No Any antibiotics (yes/no) 1,161,500 (1,212) 1.32 (1.17–1.48) p=0.40  N/A  
 Number of dispensed antibiotics  1.08 (1.05–1.12)   N/A  
   Yes Any antibiotics (yes/no) 6,941 (208) 1.07 (0.80–1.42)   N/A  
 Number of dispensed antibiotics  1.01 (0.92–1.10)   N/A  
Autoimmune disease in the motherd or 
the childe       
No Any antibiotics (yes/no) 1,144,692 (1,178) 1.36 (1.21–1.52) p=0.036  N/A  
 Number of dispensed antibiotics  1.10 (1.06–1.13)   N/A  
Yes Any antibiotics (yes/no) 23,957 (242) 1.02 (0.78–1.33)   N/A  
 
Number of dispensed antibiotics  0.98 (0.89–1.08)   N/A  
Type 1 diabetes in the mother or the 
child       
   No Any antibiotics (yes/no) 1,159,947 (1,242) 1.33 (1.19–1.49) P=0.27 534,068 (1,826) 1.21 (1.07–1.35) P=0.69 
 Number of dispensed antibiotics  1.09 (1.05–1.13)   1.09 (1.04–1.15)  
   Yes  Any antibiotics (yes/no) 8,702 (178) 1.14 (0.84–1.56)  3,389 (93) 1.09 (0.66–1.82)  
 Number of dispensed antibiotics  1.01 (0.92–1.12)   0.95 (0.73–1.25)  
Mode of delivery       
Vaginal delivery Any antibiotics (yes/no) 843,030 (1,114) 1.28 (1.14–1.45)  
447,329 
(1,631) 1.23 (1.09–1.40)  
 
Number of dispensed 
antibiotics  1.08 (1.04–1.12)   1.11 (1.05–1.16)  
Cesarean section 
(all types) 
Any antibiotics 
(yes/no) 196,511 (263) 1.34 (1.05–1.71) 
P=0.85 
(vaginal 
delivery and all 
types of 
cesarean 
section) 
90,128 
(288) 1.14 (0.86–1.50) 
P=0.69 
(vaginal 
delivery and 
all types of 
cesarean 
section) 
 
Number of dispensed 
antibiotics  1.08 (1.01–1.16)   1.02 (0.90–1.16)  
Elective cesarean 
section 
Any antibiotics 
(yes/no) 103,358 (145) 1.05 (0.75–1.46) 
P=0.12 
(vaginal 
delivery, 
elective and 
emergency 
cesarean 
section) 
34,728 
(116) 1.47 (0.96–2.24) 
P=0.31 
(vaginal 
delivery, 
elective and 
emergency 
cesarean 
section) 
 
Number of dispensed 
antibiotics  1.03 (0.92–1.17)   1.13 (1.00–1.27)  
Emergency 
cesarean section 
Any antibiotics 
(yes/no) 92,972 (118) 1.81 (1.26–2.60)  
54,970 
(171) 0.97 (0.67–1.39)  
 
Number of dispensed 
antibiotics  1.13 (1.06–1.20)   0.91 (0.74–1.13)  
Age at diagnosis       
1-4 years of age Any antibiotics (yes/no) 1,167,691 (462) 1.10 (0.91–1.33)  
536,926 
(1,388) 1.23 (1.08–1.40)  
 
Number of dispensed 
antibiotics  1.06 (0.99–1.13)   1.08 (1.02–1.14)  
5-8 years of age Any antibiotics (yes/no) 1,007,153 (414)
f
 1.49 (1.23–1.81)  291,572 (531)f 1.14 (0.88–1.48)  
 
Number of dispensed 
antibiotics  1.09 (1.03–1.15)   1.11 (1.01–1.23)  
9-19 years of age Any antibiotics 748,969 (544)g 1.34 (1.13–1.60)   N/A  
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(yes/no) 
 
Number of dispensed 
antibiotics  1.10 (1.05–1.16)   N/A  
a Odds ratio (OR) with 95% confidence interval (CI) for celiac disease when comparing children 
with dispensed systemic antibiotics in the first year of life with children with no dispensed 
antibiotics as a reference; adjusted for year of birth and sex. 
b
 Likelihood ratio test (LRT) for statistical interaction between the potential effect modifier and 
antibiotic exposure in the first year of life. 
c Prior to the first registration of celiac disease, the child was registered in the Danish National 
Patient Register with a diagnosis of type 1 diabetes (ICD-10 E10 E14), autoimmune thyroid 
disease (ICD-10 E03.9 E05 E06.3), autoimmune hepatitis (ICD-10 K73.2 K75.4), juvenile 
rheumatoid arthritis (ICD-10 M08.0), Down’s syndrome (ICD-10 Q90) or Turner’s syndrome 
(ICD-10 Q96). 
d
 Before giving birth to the child included in this study, the mother was registered in the Danish 
National Patient Register with a diagnosis of autoimmune thyroid disease (ICD-10 E05.0, E06.0, 
O09.92B, O99.2C), rheumatoid arthritis (ICD-10 M05, M06), type 1 diabetes (ICD-10 E10, 
O24.0) or celiac disease (K90.0). 
e
 Prior to the first registration of celiac disease, the child was registered in the Danish National 
Patient Register with a diagnosis of type 1 diabetes (ICD-10 E10 E14), autoimmune thyroid 
disease (ICD-10 E03.9 E05 E06.3), autoimmune hepatitis (ICD-10 K73.2 K75.4) or juvenile 
rheumatoid arthritis (ICD-10 M08.0). 
f The analyses included only children of 5 years of age or older at the end of follow-up. 
g The analysis included only children of 9 years of age or older at the end of follow-up. 
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Table 4. DNBC/MoBa: Effect of adjusting for the number of maternally reported infections 
in the child and duration of breastfeeding (0-18 months of age). 
 
Denmark 
(DNBC) 
n=55,076 (94 
cases)a 
Norway (MoBa) 
n=53,257 (464 
cases) 
Pooled 
n=108,333 (558 
cases) 
 OR (95% CI)b OR (95% CI)b OR (95% CI)b 
Answered questionnaires at 6 and 18 months of age 
(complete information on infections and breastfeeding)    
Any antibiotics 1.41 (0.91–2.19) 1.21 (1.00–1.45) 1.23 (1.02–1.44)c 
Number of dispensed antibiotics 1.13 (1.08–1.19) 1.09 (1.03–1.16) 1.11 (1.07–1.16)c 
Additionally adjusted for infectious episodes    
Any antibiotics 1.29 (0.81–2.05) 1.17 (0.97–1.41) 1.18 (0.98–1.39)c 
Number of dispensed antibiotics 1.13 (1.06–1.19) 1.08 (1.01–1.14) 1.11 (1.06–1.15)d 
Additionally adjusted for fungal infections    
Any antibiotics 1.40 (0.90–2.17) N/A N/A 
Number of dispensed antibiotics 1.13 (1.07–1.19) N/A N/A 
Additionally adjusted for duration of breastfeeding    
Any antibiotics 1.42 (0.92–2.21) 1.22 (1.01–1.46) 1.24 (1.03–1.45)c 
Number of dispensed antibiotics  1.14 (1.08–1.19) 1.09 (1.03–1.16) 1.12 (1.08–1.16)e 
a 6 children diagnosed with celiac disease before 18 months of age were excluded from the 
analyses. 
b Odds ratio (OR) with 95% confidence interval (CI) for celiac disease when comparing children 
with dispensed systemic antibiotics from 0 to 18 months of life with children with no dispensed 
antibiotics as a reference; adjusted for year of birth and sex. 
c
 The I2 test for heterogeneity: 0.0%. 
d
 The I2 test for heterogeneity: 12%. 
e
 The I2 test for heterogeneity: 25%. 
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1. Assessment of potential confounders 
1.1 Registers and variables 
From the Danish Civil Registration System
1
 we included information on date of birth, sex, identity of parents, maternal 
country of birth and date of death or emigration. Maternal country of birth was registered as the mother’s country of 
birth for immigrants and as the maternal grandmother’s country of birth for second-generation immigrants and 
categorized as Denmark, other Western country, Non-Western country. 
From the Danish Medical Birth Register,
2
 we obtained variables for birthweight, gestational age, maternal age at birth, 
maternal parity, maternal smoking during pregnancy, and maternal pre-pregnancy body mass index (BMI) (available 
from 2004 to 2010). Maternal BMI was categorized as <18.5, 18.5-25, 25-30, or ≥30 kg/m
2
. 
The Danish Population’s Education Register contains information on the highest level of completed education and 
ongoing education.
3
 We used information on maternal educational levels from the year of each child’s birth. We 
classified the educational levels as: Compulsory education: 10 years of education. Medium length: Additional four 
years of vocational education or 3 years of general education leading to a university admission certification possibly 
followed by 1-2 years of further education. Higher education: Education beyond medium length. 
From the Norwegian Medical Birth Register
4
 we included variables for sex, month and year of birth, birthweight, 
gestational age, and maternal type 1 diabetes. 
Maternal educational level was derived from Statistics Norway. We classified the educational levels as: Compulsory 
education: 10 years of education. Medium length: Additional 4 years of vocational education or 3 years of general 
education leading to a university admission certification. Higher education: Education beyond medium length. 
Season of birth was categorized as winter (December, January, and February), spring (March, April, and May), summer 
(June, July, and August), or autumn (September, October, and November). Birthweight was categorized as <2,500 
grams, 2,500-4,500 grams or ≥4,500 grams. Gestational age was categorized as <32 weeks, 32-37 weeks, 37-42 weeks, 
or ≥42 weeks. Weight for gestational age was calculated as children below or at the 10
th
 percentile, children between 
the 10
th
 and the 90
th
 percentiles, or children at or above the 90
th
 percentile for gestational age and sex. Maternal age 
at birth was categorized as <20 years, 20-25 years, 25-35 years, 35-40 years, or ≥40 years. Maternal smoking during 
pregnancy was registered as a dichotomous yes or no. 
1.2 Statistics 
To test the effect of adjusting for the potential confounders, we compared the children with non-missing information 
on the potential confounder(s) of interest in a logistic regression model including year of birth and sex with a model 
including year of birth, sex, and the potential confounder(s) (complete case analysis). Continuous variables were 
examined both as continuous variables when appropriate and categorized as indicated above. 
First we examined the effect of gestational age, weight for gestational age, season of birth, maternal parity, maternal 
educational level, and maternal age. Information on maternal smoking during pregnancy was missing for a large 
proportion of the mothers and therefore we analyzed the effect of smoking separately. 
Furthermore, we examined the effect of adjusting for potential confounders available only in the Danish cohort: 
maternal country of birth, maternal autoimmune disease diagnosed before the birth of the child, and maternal pre-
pregnancy BMI (only available 2004–2010). 
To address the issue of missing data, we analyzed the model including gestational age and weight for gestational age, 
season of birth, maternal parity, maternal education, and maternal age with multiple imputation of missing data. 
Missing data in a variable used in the analysis was seen in 4.8% of the Danish children and 4.7% of the Norwegian 
children. Imputation was conducted using multiple imputations by chained equations. For the sake of simplicity, 
variables with <2% missing data (gestational age, weight for gestational age, maternal parity, and maternal age) were 
single imputed with the mode of the variable, leaving education (Denmark: 3.2% missing. Norway: 4.0%). We 
performed 20 imputations following White.
5
 The imputation model included information on year of birth, sex, season 
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of birth, gestational age, birthweight for gestational age, maternal age, maternal educational level, maternal parity, 
mode of delivery, maternal type 1 diabetes as well as antibiotic exposure in the first year of life and diagnosed celiac 
disease. Multiple imputations of missing data did not change the conclusions (data not shown). 
 
2. Registrations of antibiotic exposure 
2.1 The Danish National Prescription Register 
Before 1996, prescriptions were issued under the parents’ CPR numbers (most often the mother’s) with indication of 
the child’s age. After 1996, all children had their own health insurance card and prescriptions were issued to the child. 
This practice was fully implemented by 2000. Prescriptions for the child issued to the mother’s CPR number were 
included in this study. To assess potential bias resulting from this, we restricted the analyses to children born in 1996–
2012 and children born in 2000-2012. The stratification did not change the conclusions (data not shown). 
 
2.2 The Norwegian National Prescription Register 
Approximately 30% of the prescriptions from the first year of life in the Norwegian National Prescription Register lack 
ID numbers (range 17%-56% per year; see Table S.1) precluding the individual-level linkage. Prescriptions with missing 
ID numbers were not included in the study and thus the exposure to antibiotics was underestimated and the children 
exposed to antibiotics were misclassified as unexposed. We have no reason to assume that this is dependent on celiac 
disease diagnosis. To examine potential bias due to missing ID numbers, we stratified the analyses according to the 
proportion of missing ID numbers: 2004–2007 (42% missing), 2008–2009 (26% missing), and 2010–2013 (20% 
missing). The association was strongest in the group with the least missing data, indicating that the misclassification of 
the exposed children as unexposed likely biased the results toward no association. Supporting this is the comparison 
of information from the Norwegian National Patient Register with maternally reported use of antibiotics in the MoBa 
showing comparable associations (see Table S.7 and Table S.8). 
 
2.3 Antibiotic exposure in the MoBa  
The questionnaires at 6 and 18 months of age asked the mothers of children participating in the MoBa about any 
medications administered to the children including antibiotics (Table S.4). As previously described, a proportion of the 
prescriptions in the Norwegian National Prescription Register lacked the ID numbers. Therefore, maternally reported 
information on the use of antibiotics in the children was added so that the analysis in the MoBa included prescriptions 
registered in the Norwegian National Prescription Register and maternally reported use of antibiotics in the 
questionnaires. For each of the age periods 0–6 months, 6–12 months, and 12–18 months, we categorized children in 
the MoBa cohort as exposed to antibiotics if the child had a registration of a dispensed antibiotic in the Norwegian 
National Prescription Register or if the mother indicated use of antibiotics in the MoBa questionnaire. For the Number 
of dispensed antibiotics we used the highest number of prescriptions in the Norwegian National Prescription Register 
or antibiotic courses indicated in the MoBa questionnaire, and added the number of prescriptions/antibiotic courses 
for each age period. The number of exposed children identified in the prescription register and the MoBa respectively 
is shown in Table S.7. We speculate that the low proportion of children with an indication of antibiotic use in the 
MoBa in the age period 6-12 months was attributable to maternal lack of recall bearing in mind that the 
questionnaires were completed when the children were 6 and 18 months of age. 
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To examine the effect of combining the information, all the analyses were performed with prescriptions registered in 
the Norwegian National Patient Register, antibiotic courses indicated in the MoBa questionnaires, and the combined 
variables. These calculations are shown in Table S.8. 
3. Definition of outcome 
To investigate the effect of outcome definition, we analyzed data with different definitions of celiac disease. In the 
Danish cohort we used one or more registration of celiac disease, two or more registrations of celiac disease, 
confirmed diagnoses as used in the main analyses (biopsy compatible with celiac disease (Marsh 2–3), anti-tissue 
transglutaminase IgA at ten or more the upper limit of normal or positive EMA test). 
In the Norwegian cohort we used one or more registrations of celiac disease and two or more registrations of celiac 
disease. Table S.9 shows that the definition of outcome does not change the conclusions. 
 
4. References 
1. Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011;39:22-5. 
2. Knudsen LB, Olsen J. The Danish Medical Birth Registry. Dan Med Bull 1998;45:320-3. 
3. Jensen VM, Rasmussen AW. Danish Education Registers. Scand J Public Health 2011;39:91-4. 
4. Irgens LM. The Medical Birth Registry of Norway. Epidemiological research and surveillance 
throughout 30 years. Acta Obstet Gynecol Scand 2000;79:435-9. 
5. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance 
for practice. Stat Med 2011;30:377-99. 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
5. Supplementary tables 
Table S.1. Registrations lacking ID numbers in the Norwegian Prescription Register. 
Year of dispense 
 
Lacking ID-number 
(%) 
Analyses stratified for year of dispense 
OR (95% CI)
a 
2004 35 
1.19 (1.02–1.40) 
2005 31 
2006 56 
2007 46 
2008 27 
1.17 (0.93–1.46) 
2009 26 
2010 19 
1.54 (1.21–1.96) 
2011 21 
2012 23 
2013 17 
a 
Odds ratio with 95% confidence interval for celiac disease when comparing children with ≥1 dispensed antibiotics to 
children with no dispensed antibiotics adjusted for year of birth and sex.  
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Table S.2. ICD-10 codes used for the generation of study variables from the Danish National Patient Register. 
Variable Included ICD 10 codes Description 
Hospital admissions in the 
neonatal period with 
infections likely to require 
antibiotic treatment 
A39 Meningococcal infection 
A40 Streptococcal sepsis 
A41 Other sepsis 
H65 Nonsuppurative otitis media 
H66.0 Acute suppurative otitis media 
H66.4 Suppurative otitis media, unspecified 
H66.9 Otitis media, unspecified 
J13 Pneumonia due to Streptococcus pneumoniae 
J14 Pneumonia due to Haemophilus influenzae 
J15 Bacterial pneumonia, not elsewhere classified 
L00 Staphylococcal scalded skin syndrome 
M00 Pyogenic arthritis 
N10 Acute tubulointestinal nephritis 
N12 Tubulointestinal nephritis, not specified 
N30.0 Acute cystitis 
N39.0 Urinary tract infection, site not specified 
P36 Bacterial sepsis of newborn 
P38 Omphalitis of newborn 
P39.0 Neonatal infective mastitis 
P39.3 Neonatal urinary tract infection 
Hospital admission with 
an infectious disease in 
the first year of life 
A00-B99 Certain infectious and parasitic diseases 
G0 Inflammatory diseases of the central nervous system 
H10 Conjunctivitis 
H65 Nonsuppurative otitis media 
H66 Suppurative and unspecified otitis media 
H67 Otitis media in disease classified elsewhere 
I00-I02 Acute rheumatic fever 
J00-J06 Acute upper respiratory infections 
J09-J18 Influenza and pneumonia 
J20-J22 Other acute lower respiratory tract infections 
J32 Chronic sinusitis 
J36 Peritonsillar abscess 
L00-L08 Infections of the skin and subcutaneous tissue 
N10 Acute tubulointestinal nephritis 
N11 Chronic tubulointestinal nephritis 
N12 Tubulointestinal nephritis, not specified as acute or chronic 
N30 Cystitis 
N34.0 Urethral abscess 
N39.0 Urinary tract infection, site not specified 
M00 Pyogenic arthritis 
M01 Direct infections of joint in infectious and parasitic diseases classified 
elsewhere 
R50.9 Fever, unspecified 
R56.0 Febrile convulsions 
P23 Congenital pneumonia 
P36 Bacterial sepsis of newborn 
P39 Other infections specific to the neonatal period 
Comorbidity associated 
with celiac disease 
E10, E14 Type 1 diabetes 
E03.9, E05, E06.3 Autoimmune thyroid disease 
K73.2 K75.4,  Autoimmune hepatitis 
M08.0 Juvenile rheumatoid arthritis 
Q90 Down’s syndrome 
Q96 Turner’s syndrome 
Maternal autoimmune 
disease 
E05.0, E06.0, O09.92B, O99.2C Autoimmune thyroid disease 
M05, M06 Rheumatoid arthritis 
E10, O24.0 Type 1 diabetes 
K90.0 Celiac disease 
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Table S.3. ATC codes used for sub-classification of systemic antibiotics. 
Subtype of antibiotics ATC code Antibiotics dispensed in the first year of life 
  Denmark 
Number per 1,000 (%) 
Norway 
Number per 1,000 (%) 
Beta-lactamase sensitive penicillins J01CE 245 (34) 91 (39) 
Penicillins with extended spectrum J01CA 399 (54) 56 (24) 
Macrolides, lincosamides, and steptogramins
a 
J01F 61 (8) 55 (24) 
Sulphonamides and trimethoprim J01E 4.2 (0.6) 20 (9) 
Systemic antibiotics not included in other subgroups
b 
J01* not included in other categories 7.6 (1) 9.2 (4) 
a 
This group includes macrolides (J01FA): Denmark: 100% of the subgroup, Norway 93% of the subgroup, and 
lincosamides (J01FF): Norway: 7% of the subgroup. 
b 
This group includes tetracyclines (J01AA), beta-lactamase-resistant penicillins (J01CF): Denmark 26% of the subgroup, 
Norway 12% the subgroup, combinations of penicillins including beta-lactamase inhibitors (J01CR): Denmark 64% of 
the subgroup, Norway 4% of the subgroup, cephalosporins (J01DB-D): Denmark (4%) of the subgroup, Norway 50% of 
the subgroup, aminoglycosides antibacterials (J01G), quinolone antibacterials (J01M), glycopeptide antibacterials 
(J01XA), polymyxins (J01XB), steroid antibacterials (J01XC01): Denmark 3% of the subgroup, imidazole derivates 
(J01XD), nitrofuratoin (J01XE): Denmark 1% of the subgroup, Norway 32% of the subgroup, and other antibacterials 
(J01XX).  
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Table S.4. Included questions from DNBC and MoBa questionnaires at 6 and 18 months of age. 
Cohort Subject Questionnaire 6 months of age Questionnaire 18 months of age 
DNBC Infections Common cold
a 
Common cold
a
 
  Loose stools/diarrhea
a 
Diarrhea
a
 
  Acute otitis media
b
 Acute otitis media
b
 
  Bronchitis (dry or loose cough)
b
 Bronchitis
b
 
  Pneumonia
b
 Pseudocroup
b
 
   Tonsillitis
a
 
   Fever≥38.5
a
 
   Pneumonia
b
 
   Scarlatina
b
 
 Fungal 
infections 
Oral thrush
a
 Oral thrush or other fungal infections
a
 
Other fungal infections
a
 
 Breastfeeding Do you breastfeed your boy/girl now? 
  Yes 
  No (→ next ques&on) 
  No, but the child gets mother’s milk from own mother 
  No, but the child gets mother’s milk from another 
woman 
  The child was never breastfed           
  Do not know 
  Do not wish to answer 
  Undefined 
  Not applicable 
Did you breast feed your child after it turned 6 months 
old? 
  Yes 
  No (→ next ques&on) 
  Do not know 
  Do not want to answer 
How old were your child when you stopped 
breastfeeding her/him every day? 
  End of daily breastfeeding: __months__weeks__days 
  Never breastfeeding 
  Do not know 
  Do not wish to answer 
  Undefined 
  Not applicable 
When did you stop breastfeeding? 
  Stop breast feeding: ___ months ___ weeks 
  Still breast feed 
  Do not know 
  Do not want to answer 
MoBa Infections Common cold
b
 Common cold
b
 
  Throat infection
b
 Throat infection
b
 
(confirmed streptococcal infection/other type of sore 
throat) 
  Ear infection
b
 Ear infection
b
 
  Bronchitis/RS virus/pneumonia
b
 Bronchitis/RS virus/pneumonia
b
 
  Gastric flu/diarrhea
b
 Gastric flu/diarrhea
b
 
  Urinary tract infection
b
 Urinary tract infection
b
 
  Pseudocroup
b
 Pseudocroup
b
 
 Breastfeeding What did you give your child to drink during the first 
week of life? 
  Breast milk 
  Water 
  Sugar water 
  Formula 
  Other, specify: ________ 
  Do not know/do not remember 
What type of milk has your baby been given since he/she 
was 6 months old? 
(You can enter more than one cross.) 
  Breast milk 
  Formula 
  Formula in case of milk intolerance 
  Whole milk (sweet) 
  Low-fat milk normal (sweet) 
  Extra low-fat milk (sweet) 
  Skimmed milk (sweet) 
  Yogurt with active Lactobacillus, all types 
  Other yogurt 
  Other types of sour milk 
  What has your child been given to drink during the first 6 
months of his/her life? 
(Enter a cross for each month you gave your child the 
relevant drink.) 
  Breast milk 
  Standard Collett formula 
  Collett formula with Omega 3 
  Standard NAN formula 
  Nan HA1 formula 
  Other milk, specify:______ 
  Water 
  Squash/Juice 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
9 
 
 Antibiotics Have your child ever been given any medication? 
  No 
  Yes 
If yes, give the name of the medicines and when they 
were given (include all types of medication, as well as 
natural medicines, taken both on a regular and 
occasional basis) 
  Name of medicine________ 
How old was your child when he/she took this 
medication? 
Have your child received any medication since the age of 
6 months? (This means any type of medication, including 
natural medicines and herbal remedies) 
  No 
  Yes 
If yes, give the name of the medication and what age 
your child was when he took it.(Include all types of 
medication, as well as natural medicines) 
  Name of medicine________________ 
How old was your child when he/she took this 
medication? 
a 
Number of episodes ≥3 days. 
b 
Number of episodes.  
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Table S.5. Distribution of selected characteristics and potential confounders by dispensed systemic antibiotic in the 
first year of life. 
Characteristic 
Denmark Norway 
No dispensed antibiotics 
in the first year of life 
(n=716,838) 
≥1 Dispensed antibiotics 
in the first year of life 
(n=451,818) 
No dispensed antibiotics  
in the first year of life 
(n=438,529) 
≥1 Dispensed antibiotics 
in the first year of life 
(n=98,928) 
 Number (%
a
) Number (%
a
) Number (%
a
) Number (%
a
) 
Celiac disease      
   Yes 805 (0.11) 622 (0.14) 1,529 (0.35) 390 (0.39) 
   No 716,033 (99.9) 451,196 (99.9) 437,000 (99.7) 98,538 (99.6) 
Sex     
   Male 347,391 (48) 252,278 (56) 219,677 (50) 56,199 (57) 
   Female 369,447 (52) 199,540 (44) 218,852 (50) 42,729 (43) 
Season of birth     
   Winter (December-February) 170,195 (24) 104,680 (23) 102,075 (23) 23,551 (24) 
   Spring (March-May) 165,286 (23) 129,008 (29) 110,441 (25) 27,891 (28) 
   Summer (June-August) 189,336 (26) 120,502 (27) 118,382 (27) 25,231 (26) 
   Autumn (September-November) 192,021 (27) 97,628 (22) 107,631 (25) 22,255 (22) 
Birthweight      
   <2,500 grams 39,155 (5) 20,769 (5) 17,460 (4) 8,632 (9) 
   2,500-4,500 grams 645,309 (90) 410,126 (91) 406,407 (93) 86,319 (87) 
   ≥4,500 grams 23,741 (3) 17,018 (4) 14,423 (3) 3,910 (4) 
   Missing 8,633 (1.2) 3,905 (0.9) 239 (-) 67 (-) 
Gestational age     
   Preterm birth (<37 weeks) 47,454 (7) 27,901 (6) 24,332 (6) 11,064 (11) 
   Term birth (≥37 weeks) 662,809 (92) 421,055 (93) 411,113 (94) 87,148 (88) 
   Missing 6,575 (0.9) 2,862 (0.6) 3,084 (0.7) 716 (0.7) 
Parity      
   First child 338,728 (47) 174,306 (39) 190,588 (43) 35,876 (36) 
   Second or more child 371,701 (52) 273,897 (61) 247,941 (57) 63,052 (64) 
  Missing 6,409 (0.9) 3,615 (0.8) 0 0 
Maternal educational level
c 
    
   Compulsory education 134,713 (19) 98,812 (22) 70,334 (16) 17,544 (18) 
   Medium length 324,113 (45) 214,981 (48) 124,131 (28) 29,823 (30) 
   Higher education 232,095 (32) 126,330 (28) 226,263 (52) 47,747 (48) 
   Missing 25,917 (3.6) 11,695 (2.6) 17,801 (4.1) 3,814 (3.9) 
Maternal age     
   <25 years old 96,338 (13) 66,174 (15) 72,274 (16) 16,462 (17) 
   25-35 years old 494,567 (69) 316,435 (70) 282,095 (64) 64,787 (65) 
   ≥35 years 125,923 (18) 69,200 (15) 84,160 (19) 17,679 (18) 
   Missing 10 (-) 9 (-) 0 0 
Smoking
c 
    
   Yes 111,403 (17) 81,974 (20) 49,035 (11) 11,418 (12) 
   No 501,358 (78) 310,140 (76) 314,994 (72) 71,210 (72) 
   Missing 28,189 (4) 17,964 (4) 74,500 (17) 16,300 (16) 
Associated co-morbidity
d 
    
   Yes 4,171 (0.58) 2,980 (0.66) N/A N/A 
   No 712,667 (99.4) 448,838 (99.3) N/A N/A 
Type 1 diabetes in the child     
   Yes 1,726 (0.24) 1,115 (0.25) 690 (0.16) 151 (0.15) 
   No 715,112 (99.8) 450,703 (99.8) 437,839 (99.8) 98,777 (99.8) 
Type 1 diabetes in the mother     
   Yes 3,469 (0.48) 2,567 (0.57) 1,966 (0.45) 609 (0.62) 
   No 713,369 (99.5) 449,351 (99.5) 436,563 (99.6) 98,319 (99.4) 
Hospitalization with infection     
   Yes 73,396 (10) 100,192 (22) N/A N/A 
   No 643,442 (90) 351,626 (78) N/A N/A 
Maternal BMI
e 
    
   <18.5 11,141 (4) 6,661 (4) N/A N/A 
   18.5-25 163,100 (60) 100,650 (56) N/A N/A 
   ≥25 78,172 (29) 59,540 (33) N/A N/A 
   Missing 19,116 (7) 13,422 (7) N/A N/A 
Maternal country of birth     
   Denmark 619,067 (86) 390,156 (86) N/A N/A 
   Other Western countries 25,706 (4) 10,984 (2) N/A N/A 
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   Non-Western countries 71,623 (10) 50,493 (11) N/A N/A 
   Missing 442 (-) 185 (-) N/A N/A 
Children participating in 
MoBa/DNBC 
No dispensed antibiotics 
in the first 18 months of 
life 
(n=21,151) 
≥1 Dispensed antibiotics 
in the first 18 months of 
life 
(n=33,931) 
No dispensed antibiotics 
in the first 18 months of 
life 
(n=32,185) 
≥1 Dispensed antibiotics 
in the first 18 months of 
life 
(n=21,072) 
 Number (%
a
) Number (%
a
) Number (%
a
) Number (%
a
) 
Maternally reported infections     
   0-3 episodes 5,782 (27) 2,932 (9) 6,113 (19) 1,844 (9) 
   4-6 episodes 7,864 (37) 8,771 (26) 10,653 (33) 4,830 (23) 
   7-9 episodes 3,686 (17) 7,239 (21) 8,215 (26) 5,673 (27) 
   ≥10 episodes 3,819 (18) 14,989 (44) 7,204 (22) 8,725 (41) 
Duration of breastfeeding     
   0-3 months 2,449 (12) 5,385 (16) 2,581 (8) 2,165 (10) 
   3-6 months 3,150 (15) 6,191 (18) 2,596 (8) 1,934 (9) 
   6-9 months 6,137 (29) 9,607 (28) 5,603 (17) 3,917 (19) 
   9-12 months 4,472 (21) 6,485 (19) 8,372 (26) 5,282 (25) 
   ≥12 months 4,943 (23) 6,263 (18) 13,033 (40) 7,774 (37) 
Maternally reported fungal 
infections 
    
   0 episodes 13,978 (66) 21,216 (63) N/A N/A 
   1-2 episodes 6,282 (30) 10,806 (32) N/A N/A 
   ≥ 3 episodes  891 (4) 1,909 (6) N/A N/A 
a 
The denominator is the total number of children without or with a registration of a dispensed antibiotic in each 
country. The percentages may not add up to 100 because of rounding. 
b 
The classification of maternal educational levels in Denmark and Norway is not straightforwardly comparable due to 
differences in the classification of educational levels: 
Denmark: Compulsory education: 10 years. Medium length: Additional four years of vocational education or 3 years of 
general education leading to a university admission certification possibly followed by 1-2 years of further education. 
Higher education: Education beyond medium length. 
Norway: Compulsory education: 10 years. Medium length: Additional 4 years of vocational education or 3 years of 
general education leading to a university admission certification. Higher education: Education beyond medium length. 
c
 Maternal smoking during pregnancy is only available in the period 1995–2010 in the Danish cohort. 
d
 Co-morbidity includes: Down’s syndrome, Turner’s syndrome, type 1 diabetes mellitus, autoimmune thyroid disease, 
juvenile rheumatoid arthritis, autoimmune hepatitis. 
e 
Only available in the period 2004–2010. 
Abbreviations: DNBC: The Danish National Birth Cohort; MoBa: The Norwegian Mother and Child Cohort Study 
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Table S.6. Effect of adjusting for potential confounders.  
Potential confounders 
included in addition to year 
of birth and sex 
Included in 
analyses 
Adjusted for year 
of birth 
Adjusted for year 
of birth and sex 
Adjusted for year of birth, 
sex and additional potential  
confounder(s) 
 Number (cases) OR (95% CI)
a 
OR (95% CI)
 a
 OR (95% CI)
 a
 
Norway     
Gestational age, weight for 
gestational age, maternal 
age, educational level, and 
parity 
512,212 (1,890) 1.21 (1.08–1.35) 1.21 (1.08–1.35) 1.25 (1.11–1.40) 
Smoking 446,657 (1,582) 1.19 (1.05–1.35) 1.20 (1.06–1.36) 1.20 (1.06–1.36) 
Denmark     
Gestational age, weight for 
gestational age, maternal 
age, educational level, and 
parity 
1,112,319 (1,396) 1.24 (1.11–1.38) 1.30 (1.17–1.45) 1.32 (1.18–1.47) 
Smoking 1,004,868 (1,327) 1.23 (1.11–1.38) 1.30 (1.16–1.45) 1.31 (1.18–1.47) 
Hospital contact with 
infection 
1,168,649 (1,420) 1.25 (1.12–1.39) 1.31 (1.18–1.46) 1.32 (1.18–1.47) 
Maternal autoimmune 
disease 
1,168,649 (1,420) 1.25 (1.12–1.39) 1.31 (1.18–1.46) 1.31 (1.18–1.46) 
Maternal country of birth 1,168,022 (1,419) 1.25 (1.13–1.39) 1.32 (1.18–1.46) 1.32 (1.19–1.47) 
Maternal BMI 419,263 (479) 1.05 (0.87–1.26) 1.10 (0.92–1.33) 1.10 (0.91–1.32) 
a 
Odds ratio (OR) for celiac disease with 95% confidence interval (CI) when comparing children with ≥1 dispensed 
antibiotics to children with no dispensed antibiotics in the first year of life.  
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Table S.7. Children categorized as exposed to antibiotics in the first 18 months of life in the MoBa cohort. 
Age period ≥1 dispensed antibiotic in the 
Norwegian National Prescription 
Register 
Indication of antibiotic use in the MoBa 
questionnaires 
≥1 dispensed antibiotic in the 
Norwegian National Prescription 
Register and indication of antibiotic 
use in the MoBa questionnaires 
 %
a 
%
b 
%
c 
0–6 months 32 94 27 
6–12 months 73 58 32 
12–18 months 72 78 53 
We categorized children in the MoBa as exposed to antibiotics if the child had a registration of a dispensed antibiotic 
in the Norwegian National Prescription Register or if the mother indicated use of antibiotics in the MoBa 
questionnaire. This was done for each of the age periods 0–6 months, 6–12 months, and 12–18 months. The table 
shows how many of the children categorized as exposed who had a registration in the Norwegian National 
Prescription Register, indication of antibiotic use in the MoBa questionnaire, or both. 
a 
Percentage of children categorized as exposed to antibiotics registered in the Norwegian National Prescription 
Register 
b 
Percentage of children categorized as exposed to antibiotics registered in MoBa 
c 
Percentage of children categorized as exposed to antibiotics registered in the Norwegian National Prescription 
Register and in MoBa  
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Table S.8. Effect of exposure definition (Table S.7) 
 Norwegian National 
Prescription Register 
MoBa Combined 
(Norwegian National Prescription Register or MoBa) 
 OR (95% CI)
a
 OR (95% CI)
a
 OR (95% CI)
a
 
Any antibiotics (0–18 months) 1.22 (1.00–1.48) 1.19 (0.98–1.44) 1.21 (1.00–1.45) 
Number of dispensed antibiotics 1.08 (1.01–1.16) 1.15 (1.05–1.27) 1.09 (1.03–1.16) 
+Adjustment for infections    
Any antibiotics (0–18 months) 1.18 (0.97–1.44) 1.15 (0.95–1.40) 1.17 (0.97–1.41) 
Number of dispensed antibiotics 1.07 (0.99–1.15) 1.13 (1.03–1.24) 1.08 (1.01–1.14) 
+Adjustment for breastfeeding    
Any antibiotics (0–18 months) 1.23 (1.01–1.49) 1.20 (0.99–1.45) 1.22 (1.01–1.46) 
Number of dispensed antibiotics 1.09 (1.01–1.16) 1.15 (1.05–1.27) 1.09 (1.03–1.16) 
a 
Odds ratio (OR) with 95% confidence interval (CI) for celiac disease when comparing children exposed to antibiotics 
in the first 18 months of life to children not exposed to antibiotics in the first 18 months of life as a reference. 
Adjusted for year of birth and sex.  
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Table S.9. Effect of outcome definition. 
Exposure 
 Denmark Norway 
≥1 registration 
( cases) 
≥2 registrations 
(cases) 
Confirmed cases 
≥1 registration ≥2 registrations 
n=1168,656 
(2,174 cases) 
n=1,168,656 
(1,781 cases) 
n= 1,168,656 
(1,427 cases) 
n=537,457 
(2,515 cases) 
n=537,457 
(1,919 cases) 
OR (95% CI)
 
 OR (95% CI)
 b
  OR (95% CI)
 b
 OR (95% CI)
 b
 
Number of cases      
Any antibiotics
b
 1.37 (1.25–1.49) 1.36 (1.24–1.50) 1.31 (1.18–1.46) 1.26 (1.14–1.38) 1.21 (1.09–1.36) 
Number of dispensed 
antibiotics
b
 
1.11 (1.08–1.13) 1.11 (1.08–1.14) 
1.08 (1.05–1.12) 
1.10 (1.05–1.15) 1.09 (1.03–1.15) 
a Odds ratio (OR) for celiac disease (defined as indicated) with 95% confidence interval (CI) when comparing ≥1 dispensed 
antibiotics or number of antibiotics courses to no dispensed antibiotics in the first year of life. Adjusted for year of birth and 
sex. 
 
